-
1
-
-
83655184724
-
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
-
1 Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 83-90
-
-
Grempler, R.1
Thomas, L.2
Eckhardt, M.3
-
2
-
-
76249133903
-
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications
-
2 Gerich, J.E., Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27 (2010), 136–142.
-
(2010)
Diabet Med
, vol.27
, pp. 136-142
-
-
Gerich, J.E.1
-
3
-
-
65349196064
-
Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes
-
3 List, J.F., Woo, V., Morales, E., et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 32 (2009), 650–657.
-
(2009)
Diabetes Care
, vol.32
, pp. 650-657
-
-
List, J.F.1
Woo, V.2
Morales, E.3
-
4
-
-
84864283226
-
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects
-
4 Ferrannini, E., Solini, A., SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol 8 (2012), 495–502.
-
(2012)
Nat Rev Endocrinol
, vol.8
, pp. 495-502
-
-
Ferrannini, E.1
Solini, A.2
-
5
-
-
84901455931
-
Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial
-
5 Häring, H.-U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
-
(2014)
Diabetes Care
, vol.37
, pp. 1650-1659
-
-
Häring, H.-U.1
Merker, L.2
Seewaldt-Becker, E.3
-
6
-
-
84885952950
-
Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial
-
6 Häring, H.-U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
-
(2013)
Diabetes Care
, vol.36
, pp. 3396-3404
-
-
Häring, H.-U.1
Merker, L.2
Seewaldt-Becker, E.3
-
7
-
-
84892477577
-
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
-
7 Kovacs, C.S., Seshiah, V., Swallow, R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2013), 147–158.
-
(2013)
Diabetes Obes Metab
, vol.16
, pp. 147-158
-
-
Kovacs, C.S.1
Seshiah, V.2
Swallow, R.3
-
8
-
-
84885954870
-
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
-
8 Roden, M., Weng, J., Eilbracht, J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 208-219
-
-
Roden, M.1
Weng, J.2
Eilbracht, J.3
-
9
-
-
83655193529
-
The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia
-
9 DeFronzo, R.A., Davidson, J.A., Del, P.S., The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 14 (2012), 5–14.
-
(2012)
Diabetes Obes Metab
, vol.14
, pp. 5-14
-
-
DeFronzo, R.A.1
Davidson, J.A.2
Del, P.S.3
-
10
-
-
84898854471
-
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis
-
10 Baker, W.L., Smyth, L.R., Riche, D.M., et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275.
-
(2014)
J Am Soc Hypertens
, vol.8
, pp. 262-275
-
-
Baker, W.L.1
Smyth, L.R.2
Riche, D.M.3
-
11
-
-
84945455839
-
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
-
11 Chilton, R., Tikkanen, I., Cannon, C.P., et al. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 1180–1193.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 1180-1193
-
-
Chilton, R.1
Tikkanen, I.2
Cannon, C.P.3
-
12
-
-
84893214045
-
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
-
12 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circ 129 (2014), 587–597.
-
(2014)
Circ
, vol.129
, pp. 587-597
-
-
Cherney, D.Z.1
Perkins, B.A.2
Soleymanlou, N.3
-
13
-
-
16544362377
-
World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure
-
13 Muller, M.J., Bosy-Westphal, A., Klaus, S., et al. World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure. Am J Clin Nutr 80 (2004), 1379–1390.
-
(2004)
Am J Clin Nutr
, vol.80
, pp. 1379-1390
-
-
Muller, M.J.1
Bosy-Westphal, A.2
Klaus, S.3
-
14
-
-
84939966139
-
Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study
-
14 Heise, T., Mattheus, M., Woerle, H.J., et al. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther 37 (2015), 793–803.
-
(2015)
Clin Ther
, vol.37
, pp. 793-803
-
-
Heise, T.1
Mattheus, M.2
Woerle, H.J.3
-
15
-
-
84899961819
-
Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial
-
15 Barnett, A.H., Mithal, A., Manassie, J., et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2 (2014), 369–384.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 369-384
-
-
Barnett, A.H.1
Mithal, A.2
Manassie, J.3
-
16
-
-
84908332537
-
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial
-
16 Ridderstrale, M., Andersen, K.R., Zeller, C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 691-700
-
-
Ridderstrale, M.1
Andersen, K.R.2
Zeller, C.3
-
17
-
-
84903511385
-
Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes
-
17 Rosenstock, J., Jelaska, A., Frappin, G., et al. Improved glucose control with weight loss, lower insulin doses and no increased hypoglycemia with empagliflozin added-on to titrated multiple daily injections of insulin in obese inadequately controlled patients with type 2 diabetes. Diabetes Care 37 (2014), 1815–1823.
-
(2014)
Diabetes Care
, vol.37
, pp. 1815-1823
-
-
Rosenstock, J.1
Jelaska, A.2
Frappin, G.3
-
18
-
-
84928196614
-
Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension
-
18 Tikkanen, I., Narko, K., Zeller, C., et al. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care 33 (2014), 420–428.
-
(2014)
Diabetes Care
, vol.33
, pp. 420-428
-
-
Tikkanen, I.1
Narko, K.2
Zeller, C.3
-
19
-
-
84979895487
-
Empagliflozin and progression of kidney disease in type 2 diabetes
-
19 Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
-
(2016)
N Engl J Med
, vol.375
, pp. 323-334
-
-
Wanner, C.1
Inzucchi, S.E.2
Lachin, J.M.3
-
20
-
-
84933523949
-
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
-
20 Skrtic, M., Yang, G.K., Perkins, B.A., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetol 57 (2014), 2599–2602.
-
(2014)
Diabetol
, vol.57
, pp. 2599-2602
-
-
Skrtic, M.1
Yang, G.K.2
Perkins, B.A.3
-
21
-
-
84920971105
-
Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus
-
21 Lytvyn, Y., Škrtić, M., Yang, G.K., et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308 (2015), F77–83.
-
(2015)
Am J Physiol Renal Physiol
, vol.308
, pp. F77-83
-
-
Lytvyn, Y.1
Škrtić, M.2
Yang, G.K.3
-
22
-
-
84908555003
-
SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
-
22 Chino Y, Samukawa Y, Sakai S, et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm Drug Dispos 2014;35:391–404.
-
(2014)
Biopharm Drug Dispos
, vol.35
, pp. 391-404
-
-
Chino, Y.1
Samukawa, Y.2
Sakai, S.3
-
23
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
23 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
-
24
-
-
84874644599
-
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
-
24 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 3:Suppl (2013), 1–150.
-
(2013)
Kidney Int
, vol.3
, pp. 1-150
-
-
-
25
-
-
84980396108
-
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)
-
25 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 2129–2200.
-
(2016)
Eur Heart J
, vol.37
, pp. 2129-2200
-
-
Ponikowski, P.1
Voors, A.A.2
Anker, S.D.3
-
26
-
-
84951906012
-
Energy balance following sodium-glucose co-transporter-2 inhibition
-
26 Ferrannini, G., Hach, T., Crowe, S., et al. Energy balance following sodium-glucose co-transporter-2 inhibition. Diabetes Care 38 (2015), 1730–1735.
-
(2015)
Diabetes Care
, vol.38
, pp. 1730-1735
-
-
Ferrannini, G.1
Hach, T.2
Crowe, S.3
|